clinical trial · NCT06590493
Doxecitine and Doxribtimine-Expanded Access
UCB BIOSCIENCES, Inc.·—·available
Thymine Kinase 2 Deficiencydoxecitine and doxribtimine
brief summary
This Expanded Access Record for doxecitine and doxribtimine includes the following managed access programs and status: * TK0113: Available * TK0115: No longer Available
started
—
primary completion
—
completion
—
last updated
Jun 5, 2026
detailed description
* TK0113: Data Collection for Patients in the Company Supported Expanded Access Program * TK0115: TREATMENT PROTOCOL FOR DOXECITINE AND DOXRIBTIMINE - Company-sponsored Intermediate-size Cohort Expanded Access Program for Doxecitine and Doxribtimine for Patients with Thymidine Kinase 2 Deficiency (TK2d) with an Age of Symptom Onset ≤ 12 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol